- Home
- MDXG vs VTYX Comparison
MDXG vs VTYX Comparison
Compare MDXG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDXG | VTYX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 990.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MDXG | VTYX |
|---|---|---|
| Price | $5.16 | $13.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | $10.67 | ★ $13.50 |
| AVG Volume (30 Days) | 1.2M | ★ 3.0M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $393,442,000.00 | N/A |
| Revenue This Year | $19.13 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.07 | ★ N/A |
| Revenue Growth | ★ 14.77 | N/A |
| 52 Week Low | $4.89 | $0.78 |
| 52 Week High | $8.65 | $25.00 |
Technical Indicators
Market Signals| Indicator | MDXG | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 73.84 |
| Support Level | $4.89 | $13.89 |
| Resistance Level | $5.21 | $13.98 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 34.82 | 43.72 |
Price Performance
Historical ComparisonAbout MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.